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Tuesday, February 18, 2014 523aphosphatidylserine (PtdSer) at the PM [1]. Previous studies have shown that
PDK1 homodimerisation is essential for its regulating activity [2].
Our goal is to elucidate the role of PtdIns(3,4,5)P3 and PtdSer in the homodi-
merisation mechanism of PDK1. Measuring Fo¨rster Resonance Energy Trans-
fer (FRET) by Fluorescence Lifetime Imaging Microscopy (FLIM) we have
studied the spatial and temporal distribution of the homodimeric population
of wild-type and point mutants of PDK1 with decreased affinity for
PtdIns(3,4,5)P3 and PtdSer on individual human breast cancer cells (SK-
BR-3) and non-cancerous mouse fibroblasts (NIH-3T3) before and after growth
factor stimulation. Based on the statistical comparison of these populations, we
have established the critical and cooperative role of both phospholipids for the
recruitment of this kinase at the PM and its subsequent regulation through the
intermolecular organisation of homodimers.
1. Lucas N and Cho W (2011) Phosphatidylserine Binding Is Essential for
Plasma Membrane Recruitment and Signaling Function of 3-Phosphoinositide-
dependent Kinase-1. J Biol Chem 286: 41265-41272.
2. Masters TA, Calleja V, Armoogum DA et al (2010) Regulation of
3-Phosphoinositide-Dependent Protein Kinase 1 Activity by Homodimeriza-
tion in Live Cells. Science Signaling 3(145): ra78.
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Approximately 20% of breast cancers (BC) are characterized by the gene
amplification and overexpression of HER2, a member of the ErbB/HER recep-
tor family. While targeted therapies against HER2 effectively delay disease
progression in this BC subtype, details of how overexpressed HER2s drive
these tumors to malignancy are still unclear. To better understand this process,
we investigated cellular responses to HER2 overexpression in individual live
cells. We developed novel single receptor diffusion analyses to probe the
spatial distribution of HER2s and determine their activation status by their
diffusivity. Surprisingly, we found that HER2 overexpression induced defor-
mation of basal cell membranes, which depended only on the HER2 density,
regardless of the receptor signaling activity. Moreover, this membrane defor-
mation lowered the focal adhesion coverage on the cell surface, which reduced
cell adhesion and increased cell motility. These findings suggest that there is a
signaling-independent role of HER2 overexpression in disease progression of
HER2 positive BCs.
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Glioblastoma multiforme (GBM) is the most clinically aggressive primary
brain tumor and is characterized by diffuse infiltration of glioma cells into brain
parenchyma, which is rich in the glycosaminoglycan hyaluronic acid (HA). The
extracellular matrix of GBM tumors is associated with aberrant HA secretion,
overexpression of the HA receptor CD44, and tissue stiffening. Here we
combine matrix engineering and genetic manipulation of GBM tumor cells
to determine the role of HA/CD44 adhesion in the outputs of cell adhesion,
migration, and invasion. We show that HA/CD44 adhesion contributes to the
mechanosensing and invasive motility of GBM tumor cells, both intrinsically
and in the context of RGD/integrin adhesion. We also find that three-
dimensional cell invasion is maximized in an HA-rich environment, but
reduction of CD44-based adhesion or addition of integrin-adhesive peptides
to the matrix suppresses invasion. While comparatively much is known about
cell-matrix mechanosensing through integrins and the role it may play in tumor
progression, our findings reveal a previously under-appreciated role of CD44
and possibly other HA-specific receptors in this process. These findings have
broad implications for the field’s fundamental understanding of how cancer
cells interact with the tumor microenvironment and suggest new therapeutic
strategies.
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HER3 (or ErbB3) is a member of the human epidermal growth factor receptor
(HER/EGFR) family of receptor tyrosine kinases. HER3 carries inactivating
mutations in its kinase domain and therefore is denoted as a pseudokinase.
Despite lacking catalytic activity, the pseudokinase domain of HER3 playsan important role in activating EGFR and HER2 kinases, resulting in potent
downstream signaling. Recent advancements in cancer research identify
HER3 as an important therapeutic target in breast, lung, gastric, ovarian and
colorectal cancers, but due to HER3’s pseudokinase status, its inhibition re-
mains a major challenge. Our past work demonstrated that the pseudokinase
domain of HER3 tightly binds ATP. This finding suggested an exciting oppor-
tunity - it might be possible to regulate HER3 signaling through modulation of
its nucleotide-binding pocket. However, due to lack of available compounds,
this idea was left untested. Here we are reporting that the allosteric activator
function of HER3 can be modulated through this site via the ATP-
competitive inhibitor bosutinib. We present a first structure of the HER3 pseu-
dokinase domain with an inhibitor, bosutinib, bound in the nucleotide-binding
site. To our knowledge, this is the first structure of any pseudokinase bound to
an inhibitor. We then perform in vitro assays to show for the first time that
HER3 function can be modulated through small molecule binding to the
nucleotide-binding pocket. Although we show that bosutinib has the opposite
effect from what is desired in cancer therapies, our study provides the proof
of principle for small molecule regulation of the HER3 function. This finding
opens an exciting direction for the generation of a new class of HER3-specific
therapeutics that directly target the pseudokinase domain.
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Trastuzumab is the most commonly used humanized monoclonal antibody for
specific therapy of breast cancer. Even though its clinical introduction was a
breakthrough, a large fraction of the treated tumors are or become resistant.
It is well known that receptor internalization and recycling are crucial
for ErbB2 mediated signal transduction. Accordingly, inhibition of its mole-
cular machinery could provide alternatives for tumor treatment. Vacuolar
Hþ-ATPase (V-ATPase) is involved in the regulation of endocytotic/recycling
pathways. Archazolid-B was described as a potent V-ATPase inhibitor, which
induces apoptosis and impairs migration of tumor cells. Based on these obser-
vations we investigated the effect of Archazolid on trastuzumab-resistant Jimt-
1 cells in vitro and in vivo. 10nM of Archazolid caused decreased membrane
ErbB2 expression, which was accompanied by the reduced relative phosphor-
ylation on Y1248 and intracellular accumulation of the receptors. As an in vivo
model, SCID mice were transplanted with Jimt-1 xenografts and treated with
Archazolid. Following administration of the V-ATPase inhibitor there was a
significant decrease in tumor growth compared to control tumors. Confocal
microscopic images of tumor sections showed heterogeneous distribution of
the proliferation marker Ki67 positivity. Tumor areas with low Ki67 nuclear
expression showed intracellular accumulation of ErbB2 molecules similarly
to the in vitro experiments, compared to high Ki67 expressing areas with prom-
inent membrane ErbB2 expression. This heterogeneity might be due to diverse
tumor-vascularization. Our results demonstrate that Archazolid can be used for
in vitro and in vivo tumor growth inhibition based on its interference with
ErbB2 recycling.
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Parkinson’s disease (PD) is a neurodegenerative disorder due to reduced dopa-
mine (DA) in the striatum and loss of DA neurons in the substantia nigra pars
compacta. Embryonic stem cells (ESCs) are an optimal source for cell therapy
for PD.We recently developed a fast (one-week) protocol using small molecules
that effectively induces human ESCs to become primitive neural stem cells
(pNSCs), which are then differentiated into DA-like neurons in vitro. As pNSCs
are infinitely expandable, this approach offers a strategy to readily generate DA
neurons on a large scale. But whether these pNSC-differentiated DA (pNSC-
DA) neurons can functionally integrate into the damaged brain is unknown.
